It has been well established that the human immune system
has the inherent capability to recognize and eliminate aberrant tissue cells in
the body that have become transformed into cancerous cells capable of
metastasis. The natural process of
finding and eliminating these cells is referred to as cancer surveillance. It is this understanding that has led to the
development of clinical approaches taking advantage of this phenomenon. The techniques employed in this regard are
classified under the heading, cancer
immunotherapy.
There is a particular subset of circulating immuno-competent
white blood cells referred to as natural killer cells that play a significant
role in the body’s response to infectious pathogens as well as in cancer
surveillance (see image below). Dr.
Rizwan Rowee and is colleagues from the Department of Medicine, Oncology
Division Washington University School of Medicine in St. Louis investigated the
properties of natural killer cells in regard to their ability to identify and
destroy cancerous cells. They were
particularly interested in their “memory” capacity. It has long been known that subsets of immuno-competent
cells retain the capacity to recognize and attack particular targets from
previous encounters. This is an indispensable
feature of a normal immune system.
Natural Killer Cells Attacking a Target Cell
Following exhaustive study and analysis of these natural
killer cells with human leukemic cells in culture, the investigators discovered
that natural killer cells with memory-like capability actually demonstrated an
anti-leukemic effect against patients with acute myeloid leukemia (AML). In some cases, this treatment led to clinical
remissions. The investigators reported
that, “Clinical responses were observed in five of nine evaluable patients,
including four complete remissions. Thus, harnessing cytokine-induced
memory-like NK cell responses represents a promising translational
immunotherapy approach for patients with AML.”
These are very important findings especially in regard to
the treatment of patients with AML; since, this disease is a particularly aggressive
form of leukemia.
No comments:
Post a Comment